Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS

Alzheimer's Disease Clinical Trial

— rTMS-AD  

Official title:

Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Enhancement of Dorsolateral Prefrontal Cortex Neuroplasticity: A TMS-EEG Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02537496
• Other study ID #: 005/2015
• Status: Completed
• Phase: N/A
• Start date: January 14, 2016
• Est. completion date: October 10, 2018

Study information

• Verified date: February 2019
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study the investigators aim at assessing and then enhancing neuroplasticity in the dorsolateral prefrontal cortex (DLPFC) and working memory - a key function of DLPFC - in patients with mild Alzheimer's disease (AD). The investigators will use Paired Associative Stimulation (PAS) paradigm to measure neuroplasticity and then a 4-week course of high-frequency repetitive Transcranial Magnetic Stimulation (rTMS) to the DLPFC to enhance cognitive function. Clinical and cognitive assessments will be done at baseline, one week, one month and 6 months after the rTMS course. Healthy controls will also be enrolled to carry out baseline cognitive assessments and a baseline measurement of neuroplasticity.

Description:

Specific aim 1: To assess working memory in participants with Alzheimer's disease (AD) and its change in response to a 4-week course of bilateral rTMS of DLPFC.

Hypothesis 1a: Compared to healthy individuals, participants with AD will be impaired on the N-back task.

Hypothesis 1b: Compared to sham rTMS, active rTMS will result in improvement on the N-back task in participants with AD at 1 week and 4 weeks after the treatment.

Specific aim 2: To assess DLPFC theta-gamma coupling during working memory performance in AD and its change in response to a 4-week course of bilateral rTMS of DLPFC.

Hypothesis 2a: Compared to healthy individuals, participants with AD will be impaired on DLPFC theta-gamma coupling during the N-back task.

Hypothesis 2b & 2c: Compared to sham rTMS, active rTMS will result in improvement in DLPFC theta-gamma coupling during the N-back task in participants with AD at 1 week and 4 weeks after the treatment.

Specific aim 3: To assess DLPFC neuroplasticity using PAS in participants with AD and its change in response to a 4-week course of bilateral rTMS.

Hypothesis 3a: Compared to healthy individuals, participants with AD will be impaired on PAS-induced neuroplasticity.

Hypothesis 3b: Compared to sham rTMS, active rTMS will result in improvement on PAS-induced neuroplasticity in participants with AD at 1 week and 4 weeks after the treatment.

Specific aim 4: To assess change in working memory, theta gamma coupling and DLPFC neuroplasticity at 6 months after the course of bilateral rTMS.

Hypothesis 4: Compared to sham rTMS, active rTMS group will perform better on measures of working memory, theta gamma coupling and PAS- induced DLPFC neuroplasticity 6 months after the course of rTMS.

Specific aim 5: To assess the change in general cognitive function at 4 weeks and 6 months after the course of bilateral rTMS.

Hypothesis 5: Compared to sham rTMS, active rTMS group will perform better on measures of general cognitive function at 4 weeks and 6 months after the course of rTMS.

Specific Aim 6: To assess insight in AD at baseline and any change in insight at 4 week and 6 month post rTMS follow up. H6: Participants with AD will have impaired insight into illness and cognitive function and they will experience improved insight at 4 week and 6 month follow up points.

Specific Aim 7: To validate a new scale for insight in AD , 'The Scale to Assess Anosognosia in Neurocognitive Disorders' (SAND) for its ability to assess insight at baseline and any change at 4 weeks and 6 month follow up points. H7: In participants with AD, SAND will be able to assess insight into illness and cognitive function at baseline, and will be able to detect change in insight at follow up points.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: October 10, 2018
• Est. primary completion date: October 10, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria for AD participants:

1. Age 55 years or above.

2. Ability to understand and speak English.

3. Confirmed Diagnosis of Probable AD by NIA-AA criteria.

4. Either not taking Cognitive enhancers or taking them at a stable dose for the last 3 months.

5. Willingness and ability to provide informed consent or an ability to assent and availability of a substitute decision maker willing to provide consent on participant's behalf.

6. Corrected visual acuity enough to read newspaper headlines.

7. Ability to hear a raised conversational voice, with hearing aids if needed.

Inclusion criteria for healthy control participants:

1. Age 55 or above.

2. Willingness and ability to speak English.

3. Willingness and ability to provide informed consent.

4. Corrected visual acuity enough to read newspaper headlines.

5. Ability to hear a raised conversational voice, with hearing aids if needed.

Exclusion Criteria for AD participants:

1. MOCA score < 10.

2. DSM IV - TR diagnosis of a current episode of mood disorder in the last 3 months.

3. DSM IV - TR diagnosis of a current anxiety disorder in the last 3 months.

4. DSM IV - TR diagnosis of a current substance use disorder in the last 3 months.

5. DSM IV - TR diagnosis of a current or lifetime primary psychotic disorder.

6. Diagnosis of intellectual disability or a neurodevelopmental disorder.

7. Electroconvulsive Therapy treatment in the last 6 months.

8. History of a seizure other than a febrile seizure in infancy.

9. Currently taking Anticonvulsants or Benzodiazepines.

10. Any contraindication for TMS or any other medical condition/circumstances that would make the study participation difficult for the participant.

Exclusion criteria for healthy control participants:

1. Meets criteria for a DSM IV - TR diagnosis other than simple phobias or Adjustment disorder.

2. Any other neurological disorder affecting central nervous system.

3. Psychotropic medication except for sedative /hypnotics at a stable dose for at least 4 weeks.

4. History of seizure other than a febrile seizure in infancy

5. Currently taking Anticonvulsants or Benzodiazepines.

6. Any contraindication for TMS or any other medical condition/circumstances that would make the study participation difficult for the participant.

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer's Disease

Intervention

Procedure:
• Repetitive Transcranial Magnetic Stimulation
Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
• Repetitive Transcranial Magnetic Stimulation - Sham
Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects

Locations

Country	Name	City	State
Canada	Center for Addiction and Mental Health	Toronto	Ontario

Sponsors (3)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health	Brain & Behavior Research Foundation, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in N-back Task Performance	The N-Back is a working memory task where the subject is presented with a sequence of stimuli (letters).; The task consists of indicating when the current stimulus matches the one from N steps earlier in the sequence. By measuring the accuracy on the N-back task, the investigators will assess the working memory at baseline and compare the change at 7days, 4 weeks and 6 months post-intervention.; The investigators' pilot data suggests that this test is most discriminatory between AD participants and healthy controls. The N-back task will be administered while recording EEG online to assess theta-gamma coupling.	pre-intervention (baseline) and then 7 days, 4 weeks and 6 months after intervention
Secondary	Changes in Theta Phase-Gamma Amplitude Coupling	Theta gamma coupling may serve as a surrogate marker of neuroplasticity and underlie working memory performance. From EEG recordings, the investigators will assess the changes in this marker from baseline at 7 days, 4 weeks and 6 months after intervention.	Change from baseline at 7 days, 4 weeks and 6 months after intervention.
Secondary	Changes in DLPFC Neuroplasticity	The investigators will use a previously established protocol to administer PAS to assess DLPFC neuroplasticity at baseline and compare the changes at 7 days, 4 weeks and 6 months after intervention.; It involves stimulation on median nerve at wrist followed by TMS of DLPFC after 25 ms delay. PAS-induced neuroplasticity will be measured as the change in TMS-induced cortical evoked activity in response to PAS and as captured with EEG.	Change from baseline at 7 days, 4 weeks and 6 months after intervention.
Secondary	Changes in Cognitive Function Measures Scores	The investigators will use an array of neuropsychological (NP) tests to measure the general cognitive functions at baseline and the change from baseline at 7 days, 4 weeks and 6 months after intervention.; The NP tests include: Executive Interview (EXIT25), Montreal Cognitive Assessment (MOCA) and Cambridge Neuropsychological Test Automated Battery (CANTAB).	Change from baseline at 7 days, 4 weeks and 6 months after intervention.
Secondary	Validating a new scale for insight in Alzheimer's disease.	The Scale to Assess Anosognosia in Neurocognitive Disorders' (SAND) is a new scale to assess insight in patients with Alzheimer's disease. It measures the core dimensions of clinical insight into AD, including general illness awareness, symptom attribution, awareness of need for treatment, and awareness of negative consequences attributable to the illness.	Change from baseline at 7 days and 6 months after intervention.

External Links

•   Description: The Centre for Addiction and Mental Health (CAMH) is the leading mental health and addictions research facility in Canada, and one of the largest in the world.